A strategy for controlling potential interactions between natural health products and chemotherapy: A review in pediatric oncology

Journal of Pediatric Hematology/Oncology

Volumn 29, Issue 1, 2007, Pages 32-47

  Seely, Dugald ^a,b   Stempak, Diana ^a   Baruchel, Sylvain ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b CANADIAN COLLEGE OF NATUROPATHIC MEDICINE   (Canada)

Author keywords

Cancer; Chemotherapy; Complementary and alternative medicine; Interaction; Natural health products; Pediatric oncology; Pharmacodynamics; Pharmacokinetics

Indexed keywords

5 METHYLSELENOCYSTEINE; 7 ETHYL 10 HYDROXYCAMPTOTHECIN; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; ANTIOXIDANT; ASCORBIC ACID; BAICALEIN; BLEOMYCIN; CISPLATIN; CURCUMIN; DAUNORUBICIN; DOXORUBICIN; FLUOROURACIL; GREEN TEA EXTRACT; HYPERICUM PERFORATUM EXTRACT; IDARUBICIN; IRINOTECAN; MELATONIN; METHOTREXATE; NATURAL PRODUCT; NAVELBINE; PLATINUM DERIVATIVE; SELENIUM; SELENIUM DERIVATIVE; SELENOKAPPACARRAGEENAN; SELENOMETHIONINE; THEANINE; UNCLASSIFIED DRUG; VINCRISTINE; WHEY PROTEIN;

ALTERNATIVE MEDICINE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CHEMOSENSITIVITY; CHILDHOOD CANCER; CLINICAL TRIAL; COLON CANCER; CONFERENCE PAPER; DISEASE EXACERBATION; DRUG MEGADOSE; HUMAN; LEUKEMIA; LYMPHOMA; MEDICAL RESEARCH; NONHUMAN; OVARY CANCER; PHYSICAL CHEMISTRY; PHYSICIAN; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS;

ADOLESCENT; BIOLOGICAL PRODUCTS; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS; COMPLEMENTARY THERAPIES; DRUG INTERACTIONS; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; MALE; NEOPLASMS;

EID: 33846438603     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e3180310521     Document Type: Conference Paper

References (155)

1. Ernst E, Cassileth BR. The prevalence of complementary/alternative medicine in cancer: a systematic review. Cancer. 1998;83:777-782.
2. Kelly KM. Complementary and alternative medical therapies for children with cancer. Eur J Cancer. 2004;40:2041-2046.
3. Jankovic M, Spinetta JJ, Martins AG, et al. Non-conventional therapies in childhood cancer: guidelines for distinguishing non-harmful from harmful therapies: a report of the SIOP Working Committee on Psychosocial Issues in Pediatric Oncology. Pediatr Blood Cancer. 2004;42:106-108.
4. Fitch MI, Gray RE, Greenberg M, et al. Nurses' perspectives on unconventional therapies. Cancer Nurs. 1999;22:238-245.
5. Martel D, Bussieres JF, Theoret Y, et al. Use of alternative and complementary therapies in children with cancer. Pediatr Blood Cancer. 2005;44:660-668.
6. Scrace J. Complementary therapies in palliative care of children with cancer: a literature review. Paediatr Nurs. 2003;15:36-39.
7. Sinha D, Efron D. Complementary and alternative medicine use in children with attention deficit hyperactivity disorder. J Paediatr Child Health. 2005;41:23-26.
8. Sparber A, Wootton JC. Surveys of complementary and alternative medicine: Part II. Use of alternative and complementary cancer therapies. J Altern Complement Med. 2001;7:281-287.
9. N. C. S. Canadian Cancer Statistics. Canadian Cancer Statistics 2000 - Cancer in Children Aged 0-19 Years. Toronto, Ontario: NCIC; 2000.
10. NHPD. Natural Health Products. Ottawa: Health Canada; 2006.
11. Mills E, Montori VM, Wu P, et al. Interaction of St John's wort with conventional drugs: systematic review of clinical trials. BMJ. 2004;329:27-30.
12. Alfaro CL, Piscitelli SC. Drug interactions. In: Atkinson AJ, Daniels CE, Dedrick RL, et al, eds. Principals of Clinical Pharmacology. San Diego: Academic Press; 2001:167-180.
13. Johnston BC, Wu P, Mills E. Herb-drug interaction implications in pediatric practice: an overview of pharmacokinetic trials. Arch Pediatr Adolesc Med. 2005;159: 692.
14. Mills E, Wu P, Johnston BC, et al. Natural health product-drug interactions: a systematic review of clinical trials. Ther Drug Monit. 2005;27:549-557.
15. Boullata J. Natural health product interactions with medication. Nutr Clin Pract. 2005;20:33-51.
16. Santos CA, Boullata JI. An approach to evaluating drug-nutrient interactions. Pharmacotherapy. 2005;25:1789-1800.
17. Foster BC, Arnason JT, Briggs CJ. Natural health products and drug disposition. Annu Rev Pharmacol Toxicol. 2005;45:203-226.
18. Venkataramanan R, Komoroski B, Strom S. In vitro and in vivo assessment of herb drug interactions. Life Sci. 2006;78:2105-2115.
19. Foster BC, Vandenhoek S, Hana J, et al. In vitro inhibition of human cytochrome P450-mediated metabolism of marker substrates by natural products. Phytomedicine. 2003;10:334-342.
20. Cerea G, Vaghi M, Ardizzoia A, et al. Biomodulation of cancer chemotherapy for metastatic colorectal cancer: a randomized study of weekly low-dose irinotecan alone versus irinotecan plus the oncostatic pineal hormone melatonin in metastatic colorectal cancer patients progressing on 5-fluorouracil-containing combinations. Anticancer Res. 2003;23:1951-1954.
21. Greish K, Sanada I, Saad Ael D, et al. Protective effect of melatonin on human peripheral blood hematopoeitic stem cells against doxorubicin cytotoxicity. Anticancer Res. 2005;25:4245-4248.
22. Lissoni P, Barni S, Mandala M, et al. Decreased toxicity and increased efficacy of cancer chemotherapy using the pineal hormone melatonin in metastatic solid tumour patients with poor clinical status. Eur J Cancer. 1999;35:1688-1692.
23. Dziegiel P, Jethon Z, Suder E, et al. Role of exogenous melatonin in reducing the cardiotoxic effect of daunorubicin and doxorubicin in the rat. Exp Toxicol Pathol. 2002;53:433-439.
24. Sugiyama T, Sadzuka Y. Enhancing effects of green tea components on the antitumor activity of adriamycin against M5076 ovarian sarcoma. Cancer Lett. 1998;133:19-26.
25. Sadzuka Y, Sugiyama T, Sonobe T. Improvement of idarubicin induced antitumor activity and bone marrow suppression by theanine, a component of tea. Cancer Lett. 2000;158:119-124.
26. Sen S, Sharma H, Singh N. Curcumin enhances vinorelbine mediated apoptosis in NSCLC cells by the mitochondrial pathway. Biochem Biophys Res Commun. 2005;331:1245-1252.
27. van't Land B, Blijlevens NM, Marteijn J, et al. Role of curcumin and the inhibition of NF-kappaB in the onset of chemotherapy-induced mucosal barrier injury. Leukemia. 2004;18:276-284.
28. Aggarwal BB, Shishodia S, Takada Y, et al. Curcumin suppresses the paclitaxel-induced nuclear factor-kappaB pathway in breast cancer cells and inhibits lung metastasis of human breast cancer in nude mice. Clin Cancer Res. 2005;11:7490-7498.
29. Fakih M, Cao S, Durrani FA, et al. Selenium protects against toxicity induced by anticancer drugs and augments antitumor activity: a highly selective, new, and novel approach for the treatment of solid tumors. Clin Colorectal Cancer. 2005;5:132-135.
30. Hu YJ, Chen Y, Zhang YQ, et al. The protective role of selenium on the toxicity of cisplatin-contained chemotherapy regimen in cancer patients. Biol Trace Elem Res. 1997;56:331-341.
31. Caffrey PB, Frenkel GD. Selenium compounds prevent the induction of drug resistance by cisplatin in human ovarian tumor xenografts in vivo. Cancer Chemother Pharmacol. 2000;46:74-78.
32. Abdel-Latif MM, Raouf AA, Sabra K, et al. Vitamin C enhances chemosensitization of esophageal cancer cells in vitro. J Chemother. 2005;17:539-549.
33. Greggi Antunes LM, Darin JD, Bianchi MD. Protective effects of vitamin c against cisplatin-induced nephrotoxicity and lipid peroxidation in adult rats: a dose-dependent study. Pharmacol Res. 2000;41:405-411.
34. Nagy B, Mucsi I, Molnar J, et al. Chemosensitizing effect of vitamin C in combination with 5-fluorouracil in vitro. In Vivo. 2003;17:289-292.
35. Prasad KN, Sinha PK, Ramanujam M, et al. Sodium ascorbate potentiates the growth inhibitory effect of certain agents on neuroblastoma cells in culture. Proc Natl Acad Sci USA. 1979;76:829-832.
36. Tsai WY, Chang WH, Chen CH, et al. Enchancing effect of patented whey protein isolate (Immunocal) on cytotoxicity of an anticancer drug. Nutr Cancer. 2000;38:200-208.
37. Clarke J, Butler R, Howarth G, et al. Exposure of oral mucosa to bioactive milk factors reduces severity of chemotherapy-induced mucositis in the hamster. Oral Oncol. 2002;38:478-485.
38. Kennedy RS, Konok GP, Bounous G, et al. The use of a whey protein concentrate in the treatment of patients with metastatic carcinoma: a phase I-II clinical study. Anticancer Res. 1995;15:2643-2649.
39. Aggarwal BB, Ichikawa H, Garodia P, et al. From traditional ayurvedic medicine to modern medicine: identification of therapeutic targets for suppression of inflammation and cancer. Expert Opin Ther Targets. 2006;10:87-118.
40. Shukla Y, Pal SK. Complementary and alternative cancer therapies: past, present and the future scenario. Asian Pac J Cancer Prev. 2004;5:3-14.
41. McCurdy EA, Spangler JG, Wofford MM, et al. Religiosity is associated with the use of complementary medical therapies by pediatric oncology patients. J Pediatr Hematol Oncol. 2003;25:125-129.
42. Blask DE, Sauer LA, Dauchy RT. Melatonin as a chronobiotic/anticancer agent: cellular, biochemical, and molecular mechanisms of action and their implications for circadian-based cancer therapy. Curr Top Med Chem. 2002;2:113-132.
43. Aggarwal BB, Kumar A, Bharti AC. Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res. 2003;23:363-398.
44. Baruchel S, Viau G. In vitro selective modulation of cellular glutathione by a humanized native milk protein isolate in normal cells and rat mammary carcinoma model. Anticancer Res. 1996;16:1095-1099.
45. Cooper R, Morre DJ, Morre DM. Medicinal benefits of green tea: Part II. Review of anticancer properties. J Altern Complement Med. 2005;11:639-652.
46. Hardman WE. (n-3) fatty acids and cancer therapy. J Nutr. 2004;134:3427S-3430S.
47. Patrick L. Selenium biochemistry and cancer: a review of the literature. Altern Med Rev. 2004;9:239-258.
48. Russell RM. The enigma of beta-carotene in carcinogenesis: what can be learned from animal studies. J Nutr. 2004;134:262S-268S.
49. Padayatty SJ, Katz A, Wang Y, et al. Vitamin C as an antioxidant: evaluation of its role in disease prevention. J Am Coll Nutr. 2003;22:18-35.
50. Welsh J, Wietzke JA, Zinser GM, et al. Impact of the vitamin D3 receptor on growth-regulatory pathways in mammary gland and breast cancer. J Steroid Biochem Mol Biol. 2002;83:85-92.
51. Park OJ, Surh YJ. Chemopreventive potential of epigallocatechin gallate and genistein: evidence from epidemiological and laboratory studies. Toxicol Lett. 2004;150:43-56.
52. Seely D, Mills EJ, Wu P, et al. The effects of green tea consumption on incidence of breast cancer and recurrence of breast cancer: a systematic review and meta-analysis. Integr Cancer Ther. 2005;4:144-155.
53. Mills E, Wu P, Seely D, et al. Melatonin in the treatment of cancer: a systematic review of randomized controlled trials and meta-analysis. J Pineal Res. 2005;39:360-366.
54. Mitchel RE, McCann R. Vitamin E is a complete tumor promoter in mouse skin. Carcinogenesis. 1993;14:659-662.
55. Styczynski J, Wysocki M. Alternative medicine remedies might stimulate viability of leukemic cells. Pediatr Blood Cancer. 2006;46:94-98.
56. Omenn GS, Goodman GE, Thornquist MD, et al. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med. 1996;334:1150-1155.
57. Mathijssen RH, Verweij J, de Bruijn P, et al. Effects of St. John's wort on irinotecan metabolism. J Natl Cancer Inst. 2002;94:1247-1249.
58. Spaulding-Albright N. A review of some herbal and related products commonly used in cancer patients. J Am Diet Assoc. 1997;97:S208-S215.
59. Mannel M. Drug interactions with St John's wort: mechanisms and clinical implications. Drug Saf. 2004;27:773-797.
60. Beijnen JH, Schellens JH. Drug interactions in oncology. Lancet Oncol. 2004;5:489-496.
61. Block KI, Gyllenhaal C. Clinical corner: herb-drug interactions in cancer chemotherapy: theoretical concerns regarding drug metabolizing enzymes. Integr Cancer Ther. 2002;1:83-89.
62. Garrison MA, Hammond LA, Geyer CE Jr, et al. A phase I and pharmocokinetic study of exatecan mesylate administered as a protracted 21-day infusion in patients with advanced solid malignancies. Clin Cancer Res. 2003;9:2527-2537.
63. Anderson GD. Children versus adults: pharmacokinetic and adverse-effect differences. Epilepsia. 2002;43(suppl 3):53-59.
64. Block KI. Antioxidants and cancer therapy: furthering the debate. Integr Cancer Ther. 2004;3:342-348.
65. D'Andrea GM. Use of antioxidants during chemotherapy and radiotherapy should be avoided. CA Cancer J Clin. 2005;55:319-321.
66. Conklin KA. Dietary antioxidants during cancer chemotherapy: impact on chemotherapeutic effectiveness and development of side effects. Nutr Cancer. 2000;37:1-18.
67. Conklin KA. Cancer chemotherapy and antioxidants. J Nutr. 2004;134:3201S-3204S.
68. Prasad KN. Multiple dietary antioxidants enhance the efficacy of standard and experimental cancer therapies and decrease their toxicity. Integr Cancer Ther. 2004;3:310-322.
69. Ladas EJ, Jacobson JS, Kennedy DD, et al. Antioxidants and cancer therapy: a systematic review. J Clin Oncol. 2004;22:517-528.
70. Kennedy DD, Tucker KL, Ladas ED, et al. Low antioxidant vitamin intakes are associated with increases in adverse effects of chemotherapy in children with acute lymphoblastic leukemia. Am J Clin Nutr. 2004;79:1029-1036.
71. Kelly KM, Jacobson JS, Kennedy DD, et al. Use of unconventional therapies by children with cancer at an urban medical center. J Pediatr Hematol Oncol. 2000;22:412-416.
72. Wang T, Chen X, Schecter RL, et al. Modulation of glutathione by a cysteine pro-drug enhances in vivo tumor response. J Pharmacol Exp Ther. 1996;276:1169-1173.
73. Baruchel S, Wang T, Farah R, et al. In vivo selective modulation of tissue glutathione in a rat mammary carcinoma model. Biochem Pharmacol. 1995;50:1505-1508.
74. Bounous G. Whey protein concentrate (WPC) and glutathione modulation in cancer treatment. Anticancer Res. 2000;20:4785-4792.
75. Panetta JC, Wilkinson M, Pui CH, et al. Limited and optimal sampling strategies for etoposide and etoposide catechol in children with leukemia. J Pharmacokinet Pharmacodyn. 2002;29:171-188.
76. Links M, Lewis C. Chemoprotectants: a review of their clinical pharmacology and therapeutic efficacy. Drugs. 1999;57:293-308.
77. Fouladi M, Stempak D, Gammon J, et al. Phase I trial of a twice-daily regimen of amifostine with ifosfamide, carboplatin, and etoposide chemotherapy in children with refractory carcinoma. Cancer. 2001;92:914-923.
78. Kim RB. Drugs as P-glycoprotein substrates, inhibitors, and inducers. Drug Metab Rev. 2002;34:47-54.
79. Mei Y, Qian F, Wei D, et al. Reversal of cancer multidrug resistance by green tea polyphenols. J Pharm Pharmacol. 2004;56:1307-1314.
80. Chow HH, Cai Y, Hakim IA, et al. Pharmacokinetics and safety of green tea polyphenols after multiple-dose administration of epigallocatechin gallate and polyphenon E in healthy individuals. Clin Cancer Res. 2003;9:3312-3319.
81. Sencer SF, Kelly KM, Iacuone J. Complementary and althernative medicine in pedatric oncology. In: Altman AJ, ed. Supportive Care of Children With Cancer. 3rd ed. Baltimore: The John Hopkins University Press; 2004:370-378.
82. Ernst E. Serious adverse effects of unconventional therapies for children and adolescents: a systematic review of recent evidence. Eur J Pediatr. 2003;162:72-80.
83. Ulbricht C, Basch E. Editors of Natural Standard. Available at: www.naturalstandard; accessed August 12, 2006.
84. Buyukavci M, Ozdemir O, Buck S, et al. Melatonin cytotoxicity in human leukemia cells: relation with its pro-oxidant effect. Fundam Clin Pharmacol. 2006;20:73-79.
85. Trubiani O, Recchioni R, Moroni F, et al. Melatonin provokes cell death in human B-lymphoma cells by mitochondrial-dependent apoptotic pathway activation. J Pineal Res. 2005;39:425-431.
86. Lissoni P, Bolis S, Mandala M, et al. Blood concentrations of tumor necrosis factor-alpha in malignant lymphomas and their decrease as a predictor of disease control in response to low-dose subcutaneous immunotherapy with interleukin-2. Int J Biol Markers. 1999;14:167-171.
87. Hardeland R. Antioxidative protection by melatonin: multiplicity of mechanisms from radical detoxification to radical avoidance. Endocrine. 2005;27:119-130.
88. Vijayalaxmi Thomas CR Jr, Reiter RJ, Herman TS. Melatonin: from basic research to cancer treatment clinics. J Clin Oncol. 2002;20:2575-2601.
89. Granzotto M, Rapozzi V, Decorti G, et al. Effects of melatonin on doxorubicin cytotoxicity in sensitive and pleiotropically resistant tumor cells. J Pineal Res. 2001;31:206-213.
90. Ursing C, Wikner J, Brismar K, et al. Caffeine raises the serum melatonin level in healthy subjects: an indication of melatonin metabolism by cytochrome P450(CYP)1A2. J Endocrinol Invest. 2003;26:403-406.
91. Hartter S, Grozinger M, Weigmann H, et al. Increased bioavailability of oral melatonin after fluvoxamine coadministration. Clin Pharmacol Ther. 2000;67:1-6.
92. Katiyar SK, Mukhtar H. Tea antioxidants in cancer chemoprevention. J Cell Biochem Suppl. 1997;27:59-67.
93. Lee MJ, Maliakal P, Chen L, et al. Pharmacokinetics of tea catechins after ingestion of green tea and (-)-epigallocatechin-3-gallate by humans: formation of different metabolites and individual variability. Cancer Epidemiol Biomarkers Prev. 2002;11:1025-1032.
94. Jodoin J, Demeule M, Beliveau R. Inhibition of the multidrug resistance P-glycoprotein activity by green tea polyphenols. Biochim Biophys Acta. 2002;1542:149-159.
95. Donovan JL, Chavin KD, Devane CL, et al. Green tea (Camellia sinensis) extract does not alter cytochrome p450 3A4 or 2D6 activity in healthy volunteers. Drug Metab Dispos. 2004;32:906-908.
96. Shi ST, Wang ZY, Smith TJ, et al. Effects of green tea and black tea on 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone bioactivation, DNA methylation, and lung tumorigenesis in A/J mice. Cancer Res. 1994;54:4641-4647.
97. Sharma RA, Gescher AJ, Steward WP. Curcumin: the story so far. Eur J Cancer. 2005;41:1955-1968.
98. Dickinson DA, Moellering DR, Iles KE, et al. Cytoprotection against oxidative stress and the regulation of glutathione synthesis. Biol Chem. 2003;384:527-537.
99. Shoba G, Joy D, Joseph T, et al. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med. 1998;64:353-356.
100. Tang XQ, Bi H, Feng JQ, et al. Effect of curcumin on multidrug resistance in resistant human gastric carcinoma cell line SGC7901/VCR. Acta Pharmacol Sin. 2005;26:1009-1016.
101. Thapliyal R, Maru GB. Inhibition of cytochrome P450 isozymes by curcumins in vitro and in vivo. Food Chem Toxicol. 2001;39:541-547.
102. Navarro-Alarcon M, Lopez-Martinez MC. Essentiality of selenium in the human body: relationship with different diseases. Sci Total Environ. 2000;249:347-371.
103. Schrauzer GN. Selenomethionine: a review of its nutritional significance, metabolism and toxicity. J Nutr. 2000;130:1653-1656.
104. Head KA. Ascorbic acid in the prevention and treatment of cancer. Altern Med Rev. 1998;3:174-186.
105. Hickey S, Roberts H. Misleading information on the properties of vitamin C. PLoS Med. 2005;2:e307; author reply e309.
106. Chiang CD, Song EJ, Yang VC, et al. Ascorbic acid increases drug accumulation and reverses vincristine resistance of human non-small-cell lung-cancer cells. Biochem J. 1994;301(Pt 3):759-764.
107. Hirsch-Ernst KI, Ziemann C, Foth H, et al. Induction of mdr1b mRNA and P-glycoprotein expression by tumor necrosis factor alpha in primary rat hepatocyte cultures. J Cell Physiol. 1998;176:506-515.
108. El-Masry EM, Abou-Donia MB. Reversal of P-glycoprotein expressed in Escherichia coli leaky mutant by ascorbic acid. Life Sci. 2003;73:981-991.
109. Wartenberg M, Hoffmann E, Schwindt H, et al. Reactive oxygen species-linked regulation of the multidrug resistance transporter P-glycoprotein in Nox-1 overexpressing prostate tumor spheroids. FEBS Lett. 2005;579:4541-4549.
110. van Heeswijk RP, Cooper CL, Foster BC, et al. Effect of high-dose vitamin C on hepatic cytochrome P450 3A4 activity. Pharmacotherapy. 2005;25:1725-1728.
111. Marshall K. Therapeutic applications of whey protein. Altern Med Rev. 2004;9:136-156.
112. Bounous G, Molson JH. The antioxidant system. Anticancer Res. 2003;23:1411-1415.
113. Ronis MJ, Rowlands JC, Hakkak R, et al. Inducibility of hepatic CYP1A enzymes by 3-methylcholanthrene and isosafrole differs in male rats fed diets containing casein, soy protein isolate or whey from conception to adulthood. J Nutr. 2001;31:1180-1188.
114. Xu H, Rajesan R, Harper P, et al. Induction of cytochrome P450 1A by cow milk-based formula: a comparative study between human milk and formula. Br J Pharmacol. 2005;146:296-305.
115. Yule SM, Boddy AV, Cole M, et al. Cyclophosphamide pharmacokinetics in children. Br J Clin Pharmacol. 1996;41:13-19.
116. Yule SM, Boddy AV, Cole M, et al. Cyclophosphamide metabolism in children. Cancer Res. 1995;55:803-809.
117. Tasso MJ, Boddy AV, Price L, et al. Pharmacokinetics and metabolism of cyclophosphamide in paediatric patients. Cancer Chemother Pharmacol. 1992;30:207-211.
118. Yule SM, Price L, Cole M, et al. Cyclophosphamide metabolism in children with Fanconi's anaemia. Bone Marrow Transplant. 1999;24:123-128.
119. Sadagopan N, Cohen L, Roberts B, et al. Liquid chromatographytandem mass spectrometric quantitation of cyclophosphamide and its hydroxy metabolite in plasma and tissue for determination of tissue distribution. J Chromatogr B Biomed Sci Appl. 2001;759:277-284.
120. Boddy AV, Yule SM. Metabolism and pharmacokinetics of oxazaphosphorines. Clin Pharmacokinet. 2000;38:291-304.
121. Groninger E, Proost JH, de Graaf SS. Pharmacokinetic studies in children with cancer. Crit Rev Oncol Hematol. 2004;52:173-197.
122. Kerbusch T, de Kraker J, Mathjt RA, et al. Population pharmacokinetics of ifosfamide and its dechloroethylated and hydroxylated metabolites in children with malignant disease: a sparse sampling approach. Clin Pharmacokinet. 2001;40:615-625.
123. Boddy AV, Yule SM, Wyllie R, et al. Pharmacokinetics and metabolism of ifosfamide administered as a continuous infusion in children. Cancer Res. 1993;53:3758-3764.
124. Athale UH, Stewart C, Kuttesch JF, et al. Phase I study of combination topotecan and carboplatin in pediatric solid tumors. J Clin Oncol. 2002;20:88-95.
125. Duffull SB, Robinson BA. Clinical pharmacokinetics and dose optimisation of carboplatin. Clin Pharmacokinet. 1997;33:161-183.
126. Burns RB, Embree L. Validation of high-performance liquid chromatographic assay methods for the analysis of carboplatin in plasma ultrafiltrate. J Chromatogr B Biomed Sci Appl. 2000;744:367-376.
127. Peng B, Boddy AV, Cole M, et al. Comparison of methods for the estimation of carboplatin pharmacokinetics in paediatric cancer patients. Eur J Cancer. 1995;31A:1804-1810.
128. Madden T, Sunderland M, Santana VM, et al. The pharmacokinetics of high-dose carboplatin in pediatric patients with cancer. Clin Pharmacol Ther. 1992;51:701-707.
129. Pang S, Zheng N, Felix CA, et al. Simultaneous determination of etoposide and its catechol metabolite in the plasma of pediatric patients by liquid chromatography/tandem mass spectrometry. J Mass Spectrom. 2001;36:771-781.
130. Kato Y, Nishimura S, Sakura N, et al. Pharmacokinetics of etoposide with intravenous drug administration in children and adolescents. Pediatr Int. 2003;45:74-79.
131. Boos J, Real E, Schulze W, et al. Investigation of the variability of etoposide pharmacokinetics in children. Int J Clin Pharmacol Ther Toxicol. 1992;30:495-497.
132. Chen CL, Rawwas J, Sorrell A, et al. Bioavailability and pharmacokinetic features of etoposide in childhood acute lymphoblastic leukemia patients. Leuk Lymphoma. 2001;42:317-327.
133. Wurthwein G, Krumpelmann S, Tillmann B, et al. Population pharmacokinetic approach to compare oral and i.v. administration of etoposide. Anticancer Drugs. 1999;10:807-814.
134. Wagner S, Erdlenbruch B, Langler A, et al. Oral topotecan in children with recurrent or progressive high-grade glioma: a Phase I/II study by the German Society for Pediatric Oncology and Hematology. Cancer. 2004;100:1750-1757.
135. Bai F, Kirstein MN, Hanna SK, et al. Determination of plasma topotecan and its metabolite N-desmethyl topotecan as both lactone and total form by reversed-phase liquid chromatography with fluorescence detection. J Chromatogr B Analyt Technol Biomed Life Sci. 2003;784:225-232.
136. Saylors RL III, Stewart CF, Zamboni WC, et al. Phase I study of topotecan in combination with cyclophosphamide in pediatric patients with malignant solid tumors: a Pediatric Oncology Group Study. J Clin Oncol. 1998;16:945-952.
137. Tubergen DG, Stewart CF, Pratt CB, et al. Phase I trial and pharmacokinetic (PK) and pharmacodynamics (PD) study of topotecan using a five-day course in children with refractory solid tumors: a pediatric oncology group study. J Pediatr Hematol Oncol. 1996;18:352-361.
138. Riccardi A, Mazzarella G, Cefalo G, et al. Pharmacokinetics of temozolomide given three times a day in pediatric and adult patients. Cancer Chemother Pharmacol. 2003;52:459-464.
139. Bomgaars L, Kerr J, Berg S, et al. A phase I study of irinotecan administered on a weekly schedule in pediatric patients. Pediatr Blood Cancer. 2006;46:50-55.
140. Gajjar A, Chintagumpala MM, Bowers DC, et al. Effect of intrapatient dosage escalation of irinotecan on its pharmacokinetics in pediatric patients who have high-grade gliomas and receive enzyme-inducing anticonvulsant therapy. Cancer. 2003;97:2374-2380.
141. Ma MK, Zamboni WC, Radomski KM, et al. Pharmacokinetics of irinotecan and its metabolites SN-38 and APC in children with recurrent solid tumors after protracted low-dose irinotecan. Clin Cancer Res. 2000;6:813-819.
142. Mugishima H, Matsunaga T, Yagi K, et al. Phase I study of irinotecan in pediatric patients with malignant solid tumors. J Pediatr Hematol Oncol. 2002;24:94-100.
143. Vassal G, Doz F, Frappaz D, et al. A phase I study of irinotecan as a 3-week schedule in children with refractory or recurrent solid tumors. J Clin Oncol. 2003;21:3844-3852.
144. Panetta JC, Kirstein MN, Gajjar A, et al. Population pharmacokinetics of temozolomide and metabolites in infants and children with primary central nervous system tumors. Cancer Chemother Pharmacol. 2003;52:435-441.
145. Estlin EJ, Lashford L, Ablett S, et al. Phase I study of temozolomide in paediatric patients with advanced cancer. United Kingdom Children's Cancer Study Group. Br J Cancer. 1998;78:652-661.
146. Post-White J, Hawks RG. Complementary and alternative medicine in pediatric oncology. Semin Oncol Nurs. 2005;21:107-114; discussion 115-124.
147. Weiger WA, Smith M, Boon H, et al. Advising patients who seek complementary and alternative medical therapies for cancer. Ann Intern Med. 2002;137:889-903.
148. Ernst E. The risk-benefit profile of commonly used herbal therapies: Ginkgo, St. John's Wort, Ginseng, Echinacea, Saw Palmetto, and Kava. Ann Intern Med. 2002;136:42-53.
149. Smith M, Mills EJ. Select complementary/alternative therapies for prostate cancer: the benefits and risks. Cancer Pract. 2001;9:253-255.
150. Verhoef MJ, Mulkins A, Boon H. Integrative health care: how can we determine whether patients benefit? J Altern Complement Med. 2005;11(suppl 1):S57-S65.
151. Yates JS, Mustian KM, Morrow GR, et al. Prevalence of complementary and alternative medicine use in cancer patients during treatment. Support Care Cancer. 2005;13:806-811.
152. Huang SM, Hall SD, Watkins P, et al. Drug interactions with herbal products and grapefruit juice: a conference report. Clin Pharmacol Ther. 2004;75:1-12.
153. Lau L, Baruchel S. Can Canada sustain paediatric phase I trials? A national survey of cancer relapse in children. Can J Clin Pharmacol. 2005;12:e222-e228.
154. Conklin KA. Chemotherapy-associated oxidative stress: impact on chemotherapeutic effectiveness. Integr Cancer Ther. 2004;3:294-300.
155. Taixiang W, Munro AJ, Guanjian L. Chinese medical herbs for chemotherapy side effects in colorectal cancer patients (Cochrane Review). Cochrane Database Syst Rev. 2005;CD004540.